Thus, ALK has been considered as an important therapeutic target for the treatment of NSCLC and various blood tumors harboring an ALK fusion (Roskoski, 2017; Kong et al., 2019; Yang and Gong, 2019; Chhikara et al., 2020; Chen et al., 2020b). The gene discussed is ALK; the disease is hematopoietic and lymphoid system neoplasm.